Efrah Ahmed Ibrahim

Dr. Efrah Ahmed Ibrahim


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in Cancer Imaging
Verified
Journal Article
Open access
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper
PSMA PET/CT has transformed prostate cancer management, yet its diagnostic utility is not absolute. It fails to detect PSMA-suppressed disease variants, including treatment-induced neuroendocrine prostate cancer (t-NEPC) and dedifferentiated tumors, and is inherently blind to second primary malignancies (SPMs). This study evaluated the additional diagnostic yield and direct clinical impact of incorporating [¹⁸F]FDG PET/CT into a systematic, indication-driven dual-tracer protocol in high-risk prostate cancer patients. In this retrospective, STROBE-compliant, single-center cohort study, 82 patients with histologically confirmed prostate cancer who underwent both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FDG PET/CT were analyzed. Clinical indications encompassed suspected SPM, suspected dedifferentiation or t-NEPC, initial staging of very high-risk disease, pre-[¹⁷⁷Lu]Lu-PSMA therapy evaluation, and equivocal PSMA findings. The primary endpoint was the proportion of patients in whom [¹⁸F]FDG PET/CT provided additional diagnostic information. Secondary endpoints included concordance analysis and the rate of management changes. Median age was 72 years (IQR 65-75). [⁶⁸Ga]Ga-PSMA-11 demonstrated superior prostate cancer detection compared to [¹⁸F]FDG (70.7% vs. 25.6%; McNemar's p < 0.0001). However, [¹⁸F]FDG PET/CT provided clinically critical additional information and directly altered management in 51.2% of patients (95% CI: 40.6-61.7%). The most impactful contributions were histopathologically confirmed SPM detection (30.5%, predominantly lung and colorectal adenocarcinomas) and identification of PSMA-negative/FDG-positive discordant disease signaling dedifferentiation. No significant correlation was found between PSMA and FDG SUVmax values (Spearman rho = 0.149, p = 0.422), underscoring their biologically distinct and complementary targets. [¹⁸F]FDG PET/CT is not a redundant adjunct to PSMA imaging; it fills a critical diagnostic blind spot. When applied through an indication-driven framework, dual-tracer imaging directly reshapes clinical decision-making in more than half of selected high-risk prostate cancer patients, enabling detection of occult malignancies and guiding pivotal treatment decisions that PSMA PET/CT alone cannot support.

21 January 2026 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
The field of nuclear medicine is experiencing an unprecedented proliferation of novel positron emission tomography (PET) tracers, with FDA-approved PET tra

18 February 2026 in Journal of Medical Imaging and Radiation Sciences
Verified
Journal Article
Closed access
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper

25 March 2026 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper
Clear cell sarcoma (CCS) and malignant melanoma share overlapping immunohistochemical profiles, particularly SOX10 and HMB45 positivity, making histopathological differentiation challenging. Distinguishing between these entities is clinically essential due to their differing prognoses and therapeutic approaches. This case highlights how fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) contributed decisively to establishing the diagnosis of CCS by following a pathologist-recommended diagnostic algorithm. A 70-year-old male presented with a progressively enlarging left scapular mass. Tru-cut biopsy revealed a malignant neoplasm positive for SOX10 and HMB45, with immunohistochemistry insufficient to differentiate CCS from metastatic melanoma. The pathology report recommended a search for a primary cutaneous melanoma, indicating that in the absence of such a lesion, the diagnosis should favor CCS. Whole-body 18F-FDG PET/CT demonstrated extensive metastatic disease involving the lungs, left adrenal gland, T11 vertebra, scapula, and a large presacral mass. Critically, no hypermetabolic cutaneous, mucosal, or nodal lesions suggestive of a primary melanoma were identified. Comprehensive dermatological evaluation was also negative for suspicious melanocytic lesions. Based on the diagnostic algorithm, histopathology, plus exclusion of a primary melanoma, the PET/CT findings supported the diagnosis of metastatic CCS. This case demonstrates that 18F-FDG PET/CT can serve as a diagnostic tool when histopathology alone is inconclusive. The absence of a primary melanoma on whole-body 18F-FDG PET/CT and clinical examination was the decisive factor favoring CCS over melanoma of unknown primary. This case underscores the limitations of MRI, which often describes CCS as a well-defined, benign-appearing mass, potentially delaying accurate diagnosis. E.A.I. contributed to the conception and design of the case report, performed the literature review, analyzed and interpreted the PET/CT imaging findings, prepared the initial manuscript draft, and completed all subsequent revisions. E.A. provided senior clinical oversight, verified the diagnostic interpretation, contributed to critical revision of the manuscript for important intellectual content, and approved the final version for submission. Both authors read and approved the final manuscript. This case report was conducted in accordance with the ethical standards of our institutional review board. Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. All data generated or analyzed during this case report are included in this published article. Article published online: 25 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

17 June 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper
A 76-year-old man with mildly elevated prostate-specific antigen (PSA, 5.44ng/mL) and a PI-RADS 5 lesion on multiparametric MRI underwent dual-tracer PET/CT. 68 Ga-PSMA PET/CT revealed focal intense uptake in one prostatic lobe, while 18 F-FDG PET/CT demonstrated avid uptake in the contralateral lobe. Histopathology confirmed synchronous high-grade prostatic adenocarcinoma (Gleason 9) and sarcomatoid carcinoma with osteosarcomatous differentiation. This discordant dual-tracer pattern highlights the complementary role of PSMA and FDG PET/CT in detecting molecularly divergent synchronous prostatic malignancies.

1 December 2025 in Clinical Nuclear Medicine Open
Verified
Journal Article
Open access
EIEfrah Ahmed Ibrahim
Efrah Ahmed Ibrahim
EAEray Alper
Eray Alper
A 71-year-old man with no history of liver disease presented with progressive left leg pain. Imaging revealed a destructive tibial lesion, but the initial biopsy was inconclusive. Whole body 18 F-FDG PET/CT demonstrated moderate metabolic activity in the tibial mass and mild uptake in an unsuspected hepatic lesion. Repeated biopsy confirmed metastatic hepatocellular carcinoma in the tibia and primary HCC in the liver. This case illustrates tibial metastasis as the initial clinical manifestation of occult HCC and underscores the value of PET/CT in detecting synchronous primary and metastatic disease.